Share on StockTwits
 

TherapeuticsMD (NASDAQ:TXMD) CEO Robert G. Finizio sold 50,000 shares of the stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $5.70, for a total value of $285,000.00. Following the completion of the sale, the chief executive officer now directly owns 22,061,586 shares in the company, valued at approximately $125,751,040. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of TherapeuticsMD (NASDAQ:TXMD) traded up 2.26% on Thursday, hitting $5.89. 725,929 shares of the company’s stock traded hands. TherapeuticsMD has a 1-year low of $1.65 and a 1-year high of $6.10. The stock’s 50-day moving average is $5.10 and its 200-day moving average is $3.6. The company’s market cap is $853.9 million.

A number of analysts have recently weighed in on TXMD shares. Analysts at Noble Financial reiterated a “buy” rating on shares of TherapeuticsMD in a research note to investors on Friday, January 10th. Separately, analysts at Cowen and Company initiated coverage on shares of TherapeuticsMD in a research note to investors on Wednesday, January 8th. They set an “outperform” rating on the stock. Finally, analysts at Stifel Nicolaus initiated coverage on shares of TherapeuticsMD in a research note to investors on Friday, November 1st. They set a “buy” rating and a $8.00 price target on the stock.

TherapeuticsMD, Inc promotes, distributes and sells certain products developed and sold by Spectrum Health Network, Inc (NASDAQ:TXMD) relative to its digital media network.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.